Pirfenidone use in a Swedish cohort of patients with pulmonary fibrosis (PF)
G. Ferrara (Stockholm, Sweden), K. Bartley (South San Francisco, CA, United States of America), A. Levine (Solna, Sweden), L. Arnheim-Dahlstrom (Solna, Sweden), K. Kirchgaessler (Basel, Switzerland), R. Linder (Solna, Sweden), C. Janson (Uppsala, Sweden), C. Sköld (Stockholm, Sweden)
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Ferrara (Stockholm, Sweden), K. Bartley (South San Francisco, CA, United States of America), A. Levine (Solna, Sweden), L. Arnheim-Dahlstrom (Solna, Sweden), K. Kirchgaessler (Basel, Switzerland), R. Linder (Solna, Sweden), C. Janson (Uppsala, Sweden), C. Sköld (Stockholm, Sweden). Pirfenidone use in a Swedish cohort of patients with pulmonary fibrosis (PF). 2202
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: